Monopar Therapeutics stock gains 3.15% as price finishes near session high

Traders Union
All News
Financial News
Monopar Therapeutics gains 3.15% today

Highlights

MNPR/USD maintains a bullish short- to medium-term trend with price trading above key moving averages but below long-term resistance.
Momentum indicators reflect buyer dominance and a strong intraday gain of 3.15%, though several oscillators indicate near-term overbought risk.
Expected price range over the coming days is $63.0994 to $69.7406, with a high probability of consolidation or upside breakout if resistance is surpassed.

Bullish impulse persists as resistance looms near MA-200

On the technical front, MNPR is trading above the MA-20 and MA-50, while remaining just below the MA-200 on the daily chart, signaling immediate resistance at the long-term moving average. The Ichimoku Kijun level at $62.8925 provides strong support. Hourly chart indicators show positive momentum, with both MACD and ADX on a buy signal. RSI and CCI are in bullish zones, Stoch RSI remains neutral, and BBP indicates overbought conditions due to pronounced buyer dominance. The Awesome Oscillator delivers a neutral reading and does not confirm the bullish momentum. The trading session saw a 2.025-point gap and the price close near its high, all amid moderate volatility. While intraday signals support further upside, extended oscillators may warrant short-term caution.

Upside breakout favored as volatility narrows trading band

Over the next several days, price action is likely to remain within the $63.0994 to $69.7406 band, a volatility range shaped by recent technical momentum. The probability of a continued upside breakout is assessed as very high, with minimal risk of a short-term decline. A move above the upper limit would open the door to higher highs, while a breakdown below the Kijun support at $62.8925 could signal a deeper retracement toward lower levels.

Anton Kharitonov, expert at Traders Union, sees Monopar Therapeutics (MNPR) showing technical strength above key averages but notes that upside may be limited by resistance at the MA-200 and overbought indicators. The lack of news flow tempers any bullish sentiment and suggests the move is driven purely by short-term technicals. He remains cautious given extended oscillators and the risk of reversal if $62.8925 is lost. "Until clear confirmation above MA-200, I treat this strength as a short-term technical rally — not a reliable trend."

Earlier, analysts noted that Monopar Therapeutics was exhibiting a bullish bias, tempered by caution over rising overbought conditions. With momentum indicators now tilted more positively and intraday performance reinforcing this strength, traders should closely monitor whether MNPR can achieve a sustained breakout above its recent volatility range, which would confirm the start of a new upward leg.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.